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Abstract
BACKGROUND: Carcinoma of the prostate (CaP) is the
most commonly diagnosed cancer in men in the United
States. Signal transduction molecules such as tyrosine
kinases play important roles in CaP. Src, a nonreceptor
tyrosine kinase (NRTK) and the first proto-oncogene
discovered is shown to participate in processes such
as cell proliferation andmigration in CaP. Underscoring
NRTK’s and, specifically, Src’s importance in cancer is
the recent approval by the US Food and Drug Admin-
istration of dasatinib, the first commercial Src inhibi-
tor for clinical use in chronic myelogenous leukemia
(CML). In this review we will focus on NRTKs and
their roles in the biology of CaP. MATERIALS AND
METHODS: Publicly available literature from PubMed
regarding the topic of members of NRTKs in CaP was
searched and reviewed. RESULTS: Src, FAK, JaK1/2,
and ETK are involved in processes indispensable to the
biology of CaP: cell growth, migration, invasion, angio-
genesis, and apoptosis. CONCLUSIONS: Src emerges
as a common signaling and regulatory molecule in mul-
tiple biological processes in CaP. Src’s relative impor-
tance in particular stages of CaP, however, required
further definition. Continued investigation of NRTKs
will increase our understanding of their biological
function and potential role as new therapeutic targets.
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Introduction
Carcinoma of the prostate (CaP) is the most commonly
diagnosed cancer in American men, consisting of more
than 33% of all new cancer cases. Though many patients
are diagnosed with CaP, it has a relatively low mortality
rate when compared to other cancers. Nevertheless, it re-
mains the third leading cause of cancer-related deaths in
men in the United States, with about 27,350 estimated CaP-
related deaths in 2006 in the United States [1]. Because
CaP growth is facilitated by androgen exposure and be-
cause androgen withdrawal leads to apoptosis of CaP
cells, the current treatment of choice for recurrent or meta-
static CaP includes castration through chemical or surgical
means. Nearly all patients, however, relapse with androgen-
independent (AI) disease after androgen ablation therapy.
Ultimately, the uncontrolled growth of AI metastatic tumors
leads to patient mortality.
Tyrosine kinases (TKs) are signaling molecules well known
for their roles in human diseases such as diabetes and cancer.
Indeed, v-Src sarcoma (Schmidt-Ruppin A-2) viral oncogene
homolog (Src), a nonreceptor tyrosine kinase (NRTK), was
the first proto-oncogene discovered. More than a quarter of
a century has passed since the discovery of Src, and the
studies on TKs are coming to fruition with the development
and use of tyrosine kinase–based target-specific therapy
such as Gleevec, Iressa, and Herceptin for therapy against
chronic myelogenous leukemia (CML), lung cancer, and breast
cancer, respectively. Dasatinib, a dual Src/v-Abl Abelson mu-
rine leukemia viral oncogene homolog (Abl) inhibitor with anti-
migratory activity in prostate cancer cells in culture was recently
approved by the US Food and Drug Administration for use in
patients with CML [2]. Further underscoring the importance of
NRTKs, AZD0530 is another dual Src/Abl inhibitor that is
currently in multicenter phase II clinical trials for multiple types
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of malignancies, including prostate cancer. In this review we
will focus on each of theNRTKsandwhat is known about their
respective roles in the biological processes of cell prolifera-
tion,migration, invasion, apoptosis, and angiogenesis in CaP.
There are several NRTK families. These are classified
based on their structural similarities (Figure 1): Abl, tyrosine
kinase nonreceptor (TnK), C-terminal Src kinase (CSK),
focal adhesion kinase (FAK), feline sarcoma oncogene/
fujinami avian sarcoma viral oncogene homolog (FeS),
Janus kinase (JaK), Src, Tec protein kinase (Tec), and
spleen tyrosine kinase (SYK). Though these NRTK families
are extensively and individually reviewed elsewhere, this
Figure 1. NRTK families and their members in a guide tree. Protein sequences are obtained from Entrez Gene and aligned using Vector NTI Advance software
(Invitrogen, Carlsbad, CA). Vector NTI Advance uses the neighbor-joining method of phylogenetic tree construction by Saitou and Nei [127]. The numbers in
parentheses after each kinase reflect the calculated distance values between pairs of analyzed sequences.
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is the first time they are summarily discussed in relation
to CaP.
Profiles of NRTKs in CaP
In 1996, Robinson et al. [3] led the first attempt at profiling the
expression of TKs in CaP. Using a modified and improved
reverse transcriptase–polymerase chain reaction approach,
they identified nine NRTKs expressed in CWR22, a CaP
xenograft. NRTKs include lymphocyte-specific protein tyro-
sine kinase (LcK), v-Yes-1 Yamaguchi sarcoma viral on-
cogene homolog 1(Yes), Abl, Abelson-related gene (ARG),
JaK1, tyrosine kinase 2 (TyK2), and endothelial/epithelial
tyrosine kinase/bone marrow X kinase (ETK/BMX). Fur-
thermore, ARG was found in several other CaP cell lines,
which include PC-3, DU145, and LNCaP. In a similar study,
Moore et al. [4] used degenerate polymerase chain reaction
against conserved kinase catalytic subdomains and found
that Abl, JaK1, JaK2, and TyK2 are expressed in surgically
removed CaP tissues. In CWR22Rv1, DU145, LNCaP and
PC3 cell lines, 18 NRTKs are expressed. This was confirmed
by our internal data and also cross-referenced with several
published reports (Figure 2).
Src Family
As the first human proto-oncogene discovered, Src’s
history spans nearly a century and has been extensively re-
viewed [5–22]. Members of the Src family include B lymphoid
Figure 2. Summary of NRTK mRNA or protein expression in CWR22Rv1, DU145, LNCaP, and PC3 cell lines based on internal data and published reports. NRTK
domain drawings and domain information were derived from Simple Modular Architecture Research Tool (SMART, Heidelberg, Germany).
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tyrosine kinase (BLK), breast tumor kinase/protein tyrosine
kinase 6 (BrK/PTK6), Gardner-Rasheed feline sarcoma
viral oncogene homolog (FGR), Fyn oncogene related to
Src, FGR, Yes (Fyn), hemopoietic cell kinase (HCK), LcK,
v-Yes-1 Yamaguchi sarcoma viral-related oncogene homolog
(Lyn), Src, Src-related kinase lacking C-terminal regulatory
tyrosine and N-terminal myristoylation sites (SRMS),Yes,
and Yes-related kinase (YRK). Of these, FGR, Fyn, LcK,
Lyn, Src, and Yes are expressed in either CaP tumor samples
or cell lines. Src, FGR, Fyn, LcK, and Lyn in particular have
been the most widely studied in CaP.
Src The premier member of its namesake family, Src is
extensively studied in cancer biology. Less is known, how-
ever, about Src biology in CaP. Though there are no pub-
lished reports of Src expression or activation levels in clinical
CaP specimens, Src is implicated in CaP through its asso-
ciation with factors that correlate positively with the pres-
ence or the progression of CaP disease, such as protein
kinase C (PKC) q, endothelial-derived gene 1 (EG-1), and
a truncated form of c-kit [23–25]. As further evidence of
Src’s possible involvement in CaP, DRS, a negative Src
regulator, is down-regulated in CaP tissues and in prostate
intraepithelial neoplasia relative to normal and benign pros-
tate hyperplasia (BPH) tissues [26]. Thus, there is circum-
stantial clinical evidence that Src plays a role in CaP through
its interactions with other factors of significance in CaP.
More is known about Src inCaP in vitro. Src is expressed in
commonly used CaP cell lines CWR22Rv1, DU145, LAPC-4,
LNCaP, and PC-3 (Figure 3). At first glance, Src protein
expression levels in CaP cell lines do not positively corre-
late with the aggressiveness, AI state, or the proliferation
rates of these cell lines. It is important to note, however,
that wild-type cellular Src is not normally constitutively ac-
tive. Its main role is to transduce signals of upstream activa-
tors. In cancer, the upstream signals may be aberrant, thus
leading to improper activation of Src and its downstream
pathways. One such pathway in CaP is Src activation by
neuroendocrine ligands [27].
Neuroendocrine differentiation in CaP is theorized to be in
part responsible for the development of AI CaP through the
secretion of neuroendocrine ligands. There is evidence that
Src takes part in AI cell proliferation. Cyclic adenosine mono-
phosphate (cAMP) analogs are able to activate Src fol-
lowing neuroendocrine differentiation, perhaps secondary to
secreted neuroendocrine factors such as gastrin-releasing
peptide and lysophosphatidic acid (LPA) [28–31]. LPA is
thought to promote cell proliferation through the v-Ha-ras
Harvey rat sarcoma viral oncogene homolog (Ras)–v-raf-1
murine leukemia viral oncogene homolog 1 (Raf)–ERK1/2
pathway in Src-dependent fashion. Bombesin, a Xenopus
gastrin-releasing peptide homolog, can also activate ERK1/2
through Src, possibly through epidermal growth factor (EGF)
receptor transactivation [32]. Once ERK1/2 has been acti-
vated, it can then activate the androgen receptor (AR) in an
AI manner, which promotes cell growth [27,33]. In addition
to LPA and bombesin, non-neurotrophic factors such as
interleukin-8 (IL-8) and insulin-like growth factor-1 (IGF-1)
also promote AI cell growth through Src [34,35].
In addition to cell proliferation, Src also takes part in
antiapoptotic pathways in CaP. Bombesin, endothelin
(ET1), met proto-oncogene (Met), and dihydrotestosterone-
activated AR all inhibit apoptosis through Src activation
[26,36–38]. There is, however, no consensus mechanism
by which Src promotes cell survival. Nuclear factor nB
(NF-nB)–v-akt murine thymoma viral oncogene homolog 1
(Akt)–p21-associated kinase 1 (PAK1) pathway, MEK1/2–
ERK1/2–CREB pathway, and signal and transducer of
transcription 3 (STAT3)–dependent down-regulation of
B-cell lymphoma leukemia (BCL-xL) and myeloid cell leuke-
mia sequence 1 (MCL-1) are all pathways by which Src
inhibits apoptosis [39].
Src is involved in other aspects of CaP biology: cell migra-
tion and adhesion. Src interacts with the extracellular signals
through the IL-8 receptor, Met, b1 integrins, Kangai 1/cluster
designation 82 (KAI1/CD82), and CD44 [23,34,40,41]. CD44
is a cell surface glycoprotein involved in cell–cell and cell–
matrix adhesions. KAI1/CD82 functions as a metastasis
suppressor, disrupting integrin-induced Src activation [42].
Intracellularly, Src modulates cell migration and adhesion
through its interaction with FAK and p130 CRK-associated
substrate (p130CAS) [2].
In addition to cell migration, Src also assists in tumor in-
vasion through its regulation of matrix metalloproteinases
(MMPs). MMPs aid in invasion through the degradation of
the extracellular matrix. Bombesin promotes Src-dependent
tumor progression and metastasis through the activation of
MMP9 in conjunction with b1 integrins [43]. Src inhibition, on
the other hand, decreases MMP9 activity levels [2,44].
Induction of angiogenesis bymalignant cells is required for
continued cell proliferation and metastasis, and vascular
endothelial growth factor (VEGF) is a critical angiogenic
factor. Src participates in angiogenesis in CaP through the
JaK1–STAT3–VEGF pathway [45]. Src activation is also
required for VEGF expression in simulated hypoxia environ-
ment through increased levels of hypoxia-inducible factor 1a
(HIF-1a) and activation of STAT3; as additional evidence of
Src’s involvement in angiogenesis, overexpression of active
Src leads to increased VEGF expression [46]. Expression
of the melanoma-differentiation–associated gene-7, a Src
Figure 3. Western blot analysis of total Src protein expression levels in
prostate cancer cell lines. Src is shown as a doublet upon probing in most cell
lines. Internal overexpression data (not shown) indicate that both bands are
Src and that the doublet is not a result of nonspecific probing of other Src
family kinase members.
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inhibitor, on the other hand, inhibits the subsequent down-
stream STAT3–VEGF pathway [46,47].
Src is also of particular interest in CaP in part because
of its interaction with steroid receptors. There is evidence
that low amounts of AR and androgen lead to Src activation
in the cytoplasm, thereby triggering downstream signaling
events independent of AR’s transcriptional and DNA-binding
activity [38,48]. In fact, dominant negative Src can inhibit
DNA synthesis following stimulation with low amounts of
synthetic androgen. AR overexpression and higher con-
centrations of androgen, however, seem to bypass the Src
pathway, leading to AR translocation to the nucleus and AR-
transcriptional activity–based DNA synthesis.
In addition to the aforementioned activation of Src by
androgen-activated AR, Src also associates with AR and
estrogen receptor (ER) upon stimulation with estradiol, ulti-
mately resulting in increased cell proliferation [38,49,50]. It
is thought that Src serves as a scaffolding protein for the
AR–ER complex. Steroidal ligand, however, is not necessary
for AR–Src complex formation. Upon EGF stimulation, pre-
formed heterodimers of ERa and AR form a complex with
EGF receptor and Src, resulting in the activation and phos-
phorylation of EGF receptor, DNA synthesis, and cytoskeletal
changes [51]. On the other hand, DOC-2/DAB2, a tumor
suppressor and a negative Src regulator protein, is reported
to inhibit AR’s mitotic effects through the disruption of the
AR–Src complex [52,53]. Thus, taken together with reports
of AI AR activation by Src, AR and Src seem to be able to
reciprocally transactivate, depending on the concentration
and type of stimulatory ligand.
There are few published reports on cellular elements
that negatively regulate Src in CaP. In addition to DOC-2/
DAB2, tumor growth factor (TGF) b is reported to decrease
both Src expression and its corresponding activity. This is
shown by the accumulation of unphosphorylated form of
SH2-containing protein (SHC) and a subsequent decrease
in complex formation between SHC and growth factor
receptor–bound protein 2 (Grb2) [54].
BrK/PTK6 BrK is an Src family member, and little is known
about it in CaP. In patient samples, BrK is detected in
the nuclei of normal luminal epithelial tissues and well-
differentiated tumors, but not in poorly differentiated tumors
[55]. Localization of BrK in CaP cell lines LNCaP, which is
poorly tumorigenic, and PC-3, which is more aggressive, is
primarily nuclear and cytoplasmic, respectively. ThoughPC-3
expressed more BrK than LNCaP did, BrK is less active in
PC-3 cells. Thus, the localization of BrKmay play a role in the
differentiation of CaP and its aggressiveness.
FGR/Src-2 FGR is an Src kinase family member. It is a
negative regulator of phosphatase and tensin homolog
(PTEN) and a positive regulator of both Ras and Raf1, thus
inhibiting apoptosis and stimulating cell growth, respectively
[56]. Though little is known about FGR in CaP, FGR may be
overexpressed in CaP, as shown by FGR DNA amplifica-
tion in patient tumor tissues transitioning from androgen-
dependent to AI states [56]. Thus, FGR may play a role in
CaP growth and survival.
Fyn Fyn is an Src family kinase member. It is involved in
LNCaP mitogenesis following prolactin stimulation [57].
Though it is suggested that Fyn participates in prolactin-
induced cell proliferation through K+ ion channels, further
studies are necessary in order to elucidate the mechanism of
Fyn-modulated prolactin-induced cell proliferation in CaP.
LcK LcK is an Src family kinase member. It is expressed
in CWR22 xenograft cells [3]. Little else is known about the
role of LcK in CaP.
Lyn Lyn is an Src family kinase member expressed in
normal prostate, 95% of primary CaP, and AI PC-3 and
DU145 cells [58]. Lyn knockout mice have abnormal prostate
gland development. Treatment with KRX-123, a Lyn-specific
inhibitor, results in the inhibition of cell growth in DU145
and PC-3 cell lines. DU145 explants in mice treated with
KRX-123 were found to also undergo apoptosis. Thus, Lyn
seems to play a role in the proliferation and the apoptosis
of CaP.
Lyn may also be an important regulator of cell migration in
CaP. DU145 cells treated with dasatinib, an Src family kinase
inhibitor, have reduced migratory activity [2]. On the other
hand, Lyn can bind with neutral endopeptidase (NEP) and
act as a competitive inhibitor to the PI3K–FAK complex, re-
sulting in decreased cell migration [59]. Lyn’s role in CaP cell
migration is therefore inconclusive.
In CaP, Lyn is down-regulated by TGFb and up-regulated
by KAI1/CD82 [54,60]. Despite its elevated expression fol-
lowing KAI1/CD82 stimulation, however, Lyn’s overall kinase
activity was unchanged.
FAK Family
FAK As the predominate member of its namesake family
of kinases, FAK is well studied in CaP. Several general re-
views of FAK are available [61–71]. Though FAK may play
roles in growth, apoptosis, and angiogenesis in CaP, FAK is
known primarily for its role in cell motility and cytoskeletal
rearrangement, as supported by in vivo and in vitro evidence.
In clinical specimens, FAK expression and activation are
uniformly higher in metastatic CaP than in normal and BPH
tissues [72,73]. In vitro comparison between highly meta-
static CaP cell lines and LNCaP, a cell line with lower
metastatic potential, shows similar results, with increased
expression and activation of FAK in the more aggressive cell
lines [74]. FAK’s association with molecular mediators of cell
migration and adhesions are indicative of its function as well.
Activated FAK complexes with b1 and a(v)b3 integrins, mole-
cules involved in cell adhesion [75–78]. As further evidence
of FAK’s function as a cell motility factor, inhibition of FAKwith
anti-FAK (pY397) antibody or FAK-related nonkinase (FRNK)
resulted in significantly decreased cell migration [79].
Bombesin and IL-8 are both G protein–coupled receptors
(GPCR) that activate FAK and stimulate cell migration
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[34,79–81]. This is not surprising given FAK’s reciprocal
transactivation relationship with Src and both IL-8 and bomb-
esin’s abilities to activate Src. For bombesin to activate FAK,
however, both PKC and an intact cytoskeleton are required
[80,82]. Following its activation, FAK then phosphorylates
p130CAS, leading to p130CAS–v-crk avian sarcoma virus
CT10 oncogene homolog (CRKII) complex formation. Dis-
ruption of the p130CAS–CRKII complex by overexpressing
KAI1/CD82 results in decreased cell motility [60].
Extracellularly, FAK is activated by integrins, ET1, bomb-
esin, IL-8, and urokinase plasminogen activator (uPA),
an invasion and metastasis factor in CaP [83,84]. Intra-
cellularly, it is modulated by Src. It is important to note that
Src and FAK activation often go hand in hand. They couple
and reciprocally transactivate each other. There are, how-
ever, exceptions. FAK activation by autophosphorylation of
tyrosine 397 is not Src-dependent; it is adhesion-dependent
[74]. On the other hand, phosphorylation of tyrosine 861,
which leads to increased FAK activity, is Src-dependent but
not adhesion-dependent.
Though FAK is primarily a cell motility regulator, it is
also involved in cell proliferation. Similar to cell migration,
bombesin-induced FAK-mediated proliferation requires an
intact cytoskeleton [80]. A signal downstream of FAK is
ETK/BMX, an NRTK critical for bombesin-induced growth
[27]. Following FAK activation of ETK/BMX, ETK/BMX sub-
sequently activates AR, thereby inducing cell growth. Inter-
estingly, not only can FAK indirectly activate AR, it can
also be activated by membrane-associated AR in a PI3K-
dependent manner [85].
In addition to migration and proliferation, FAKmay also be
involved in CaP angiogenesis and apoptosis. There is evi-
dence that FAK induces VEGF transcription in an ERK1/
2–dependent, Rap1-dependent, and Raf-dependent but
Ras-independentmanner [86]. IncreasedVEGF transcription
may then lead to an increased level of its secreted protein
and, thus, angiogenesis. In regard to apoptosis, treatment of
cells with proapoptotic factors FTY720 and doxazosin both
down-regulate FAK expression for reasons that are not
currently known [87,88].
There are few known ways in which FAK is negatively
regulated in CaP. Negative FAK regulators include PTEN,
a tumor suppressor gene with dual phosphatase activity
that is frequently deleted in aggressive CaP [89]. FAK may
also be indirectly negatively regulated through the forma-
tion of the Lyn–PI3K–NEP complex instead of the PI3K–
FAK complex [59].
Proline-rich tyrosine kinase 2/cell adhesion kinase  (PYK2/
CAK) PYK2/CAKb is a member of the FAK family of
tyrosine kinases. A general review of PYK2 is available
[90]. It is expressed in normal prostate epithelia and BPH,
but its expression level decreases with increasing grade
in CaP [91]. The gene is located on chromosome 8p21.1,
a site of frequent deletion in CaP [92].
Though in vivo evidence suggests that PYK2 plays a
tumor suppressive role in CaP, the in vitro evidence of this
hypothesis is inconclusive. In vitro experiments show that
PYK2 is activated by LPA and tumor necrosis factor a.
PYK2 plays a role in the activation of ERK1/2 following LPA
stimulation and may thus stimulate cell proliferation [93].
In addition, cells expressing dominant negative PYK2 have
decreased proliferation rates. On the other hand, PYK2
indirectly inhibits AR activation through the inactivation of
an AR-associated protein, ARA55 [94]. Thus, PYK2’s role
in CaP may depend on the androgen sensitivity status of
the cells in question and requires further investigation
and clarification.
FeS Family
The FeS family of NRTKs consists of two members: FeS/
FpS and FpS/FeS–related tyrosine kinase (FeR). Little is
known about the FeS family in CaP. An examination of CaP
cell lines PC-3, PC133, and PC135 failed to detect FeS
transcript [95]. FeR expression, on the other hand, was found
in CaP cell lines PC-3, DU145, and LNCaP and positively
correlated with CaP versus normal and BPH tissue samples
[96]. Consistent with patient sample data, cells transfected
with antisense FeR grew at a slower rate and were unable to
grow in an anchorage-independent fashion. In the dogmodel,
a higher FeR expression was found in dividing versus resting
prostate epithelial cells and in cells displaying basal cell
hyperplasia and metaplasia following postcastration estro-
gen treatment [96]. Thus, FeR is likely a proliferation factor
in CaP.
JaK Family
JaK1 The JaK family of kinases is well known for its role
in signaling events in cells following cytokine stimulation
and its association with the STAT family of kinases. Though
JaK1 is present in some clinical CaP specimens, JaK1 is
reported to be either negatively regulated or mutated in
many CaP cell lines [4,97,98]. LNCaP is found to have both
nonsense mutation and repressed JaK1 transcription where-
as CWR22Rv1 and LAPC-4 have only nonsense mutations
and no known transcriptional repression.
In DU145 cells, which have wild-type JaK1, there are
reports that JaK1 associates with breast cancer susceptibility
gene 1 (BRCA1) [99]. When BRCA1 is overexpressed, JaK1
and STAT3 become activated. Subsequent inhibition of
STAT3 activation results in decreased cell proliferation as
well as in apoptosis. Interestingly, inhibition of JaK1 in wild-
type DU145 does not result in apoptosis [100]. Thus, it may
be possible that although JaK1 activation by BRCA1 leads
to increased JaK1 and STAT3 activation, STAT3 may in fact
not be directly downstream of JaK1 in CaP, and their con-
current activation is coincidental.
JaK1may also play a role in the inhibition of CaPmigration
and invasion following IL-10 stimulation [101]. Tissue inhibitor
of metalloproteinases (TIMP) 1 is an anti-invasion factor.
IL-10 is known to activate the JaK1–IL-10E1–TIMP-1 path-
way in CaP [102].
JaK2 JaK2 is expressed in someCaP tissues [4]. Similar to
JaK1, JaK2 is also activated by BRCA1 in DU145 cells [99]. It
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is interesting to note that although JaK1 inhibition does not
result in apoptosis in wild-type DU145 cells, inhibition of JaK2
does [100]. Thus, STAT3 activation in DU145 may be de-
pendent on JaK2 rather than on JaK1. Whether STAT3 is
activated by JaK1 or JaK2 in CaP, however, seems to be
cell line–dependent [103].
JaK2 may also be involved in cell proliferation in CaP.
Tyrosine kinase inhibitor peptide (TKIP) directly inhibits
JaK2 autophosphorylation, decreases STAT3 activation,
and slows CaP proliferation [104]. Consistent with decreased
cell proliferation and STAT3 activation, cyclin D1 level is de-
creased and cells are arrested in the G1 phase of the cell
cycle following TKIP treatment. Thus, JaK2may be important
for CaP growth through the STAT3 pathway. In addition
to STAT3, JaK2 may be of particular importance in CaP
through its regulation of STAT5, a factor that positively
correlates with the histological grade of CaP [105,106].
TyK2 TyK2 is expressed in some CaP tissues [4]. Though
TyK2 may also be involved in CaP migration and invasion
and similarly participates in the activation of IL-10E1 fol-
lowing IL-10 stimulation of CaP cells as JaK1, its temporal
regulation profile is different from that of JaK1 [101,102].
Members of Other NRTK Families
Abl Abl is well known for its role in the etiology of CML
following the formation of the Philadelphia chromosome
(t(9:22)) and the breakpoint cluster region (Bcr)–Abl hybrid
gene product. Less is known, however, about Abl in CaP.
It is known that Abl is expressed in some CaP specimens
and that Abl is necessary for retinoblastoma-mediated g-
radiation– induced apoptosis in DU145 cells [4,107]. There
is indirect evidence that Abl may be important in CaP. Human
spectrin SH domain–binding protein 1 (Hssh3bp1) is a gene
that binds to Abl, possibly as a negative regulator [108]. A
majority (9 of 17) of CaP tumor samples analyzed failed
to express Hssh3bp1. Furthermore, Hssh3bp1 is found on
chromosome 10p, a region frequently deleted in CaP. Thus,
Abl may be circumstantially implicated in CaP through its
association with Hssh3bp1.
Imatinib mesylate (Gleevec; Novartis, East Hanover, NJ)
is a Bcr–Abl inhibitor that is clinically used for the treatment
of CML. It also has activity against Kit kinase and platelet-
derived growth factor (PDGF) receptor. In vitro, Gleevec in-
hibits CaP cell growth with IC50 in the 10-mM range [109]. In
mice models, however, Gleevec’s efficacy against CaP
growth is inconclusive with some, but not all, studies showing
growth inhibition [110–113].
Similarly, preliminary results from clinical studies also paint
a mixed picture. A phase I clinical trial of Gleevec in combi-
nation with docetaxel in AI CaP showed a prostate-specific
antigen (PSA) decline in 14 of 21 patients, although it is un-
known whether the decline can be attributed to Gleevec or
docetaxel [114]. In another AI CaP study, Gleevec in com-
bination with zoledronic acid (Zometa, Novartis) showed
no clinical effect in 15 CaP patients [115]. Lastly, as mono-
therapy in 16 patients with androgen-sensitive CaP, Gleevec
treatment resulted in nine patients with stable PSA levels
and seven patients with PSA progression [116]. Thus, clinical
use of Gleevec as monotherapy in CaP may be ineffective.
The efficacy of using Gleevec as an adjuvant therapy to other
treatment modalities is presently unknown.
CSK CSK is a well known negative Src regulator [117].
Little is directly known about CSK in CaP other than that it
complexes with FAK inmetastatic tumors and PC-3 cells [73].
ETK/BMX Discovered in 1994, ETK/BMX belongs to the
Tec family of NRTK [118]. In CaP, ETK is downstream of
PI3K in the induction of the neuroendocrine differentiation
of LNCaP cells following IL-6 stimulation [119]. It is also re-
ported to function as an antiapoptotic factor. Overexpression
of ETK confers resistance to apoptosis in CaP cells through
its interaction with PI3K [120]. PI3K is not, however, required
for ETK activation [27]. Another mechanism by which ETK
may protect against apoptosis is through its interaction with
p53 [121]. Interestingly, ETK also participates in the apoptotic
cascade in CaP cells. Introduction of ETK’s C-terminal frag-
ment into PC-3 cells can lead to apoptosis following proteo-
lytic cleavage of ETK by caspases [122].
ETK is also critical for cell proliferation following bombesin
stimulation and AR activation in CaP [27]. ETK serves as a
signal transducer between Src and FAK upstream and AR
downstream. ETK alone, however, is insufficient for AR ac-
tivation. ETK must be able to reciprocally transactivate with
Pim1 before AR activation [123,124].
Other NRTKS SYK and TNK1 are other NRTKs that have
been studied in CaP. Virtually nothing is known about their
properties and functions in prostate cancer except that the
promoter region of SYK is hypermethylated and TNK1 tran-
script is found in prostate tissues [125,126]. SYK expression
may thus be down-regulated in CaP, whereas TNK1 protein
expression level remains to be investigated.
Conclusion
Much is known regarding specific NRTKs in CaP (Src, FAK,
JaK1/2, and ETK), whereas less is known about the other
NRTKs. Perhaps it is not a coincidence that the well-studied
Src, FAK, JaK1/2, andETK kinases are involved in processes
indispensable to the pathology of CaP: cell growth, migration,
invasion, angiogenesis, and apoptosis. It is therefore im-
perative that we learn more about these NRTKs through
future studies. Although Src, FAK, JaK1/2, and ETK are im-
portant in CaP biology, we should not neglect the other
NRTKs that may also play important roles in CaP and should
also investigate the lesser known NRTKs.
Looking at the current literature of NRTKs in CaP, there
emerges a picture of Src being an ubiquitous player in
multiple biological processes interacting with numerous play-
ers in multiple signaling pathways. Src transduces signals
from upstream receptors such as IL-8, EGF, IGF-1, neuro-
tensin, ET1, and HGF/SF to downstream molecules such as
FAK, ETK, JAK1/2, STAT3, Ras, ERK1/2, Akt, HIF-1a, and,
of particular significance in CaP biology, AR (Figure 4). Given
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the preponderance of evidence in multiple biological pro-
cesses linking Src to CaP, Src is likely an important point
of pathway convergence in CaP. Perhaps it is not sur-
prising then that Src is currently the only NRTK target in
clinical trials for CaP, whereas no NRTK-specific therapy is
available for general clinical use in CaP. What remains
unclear, however, is Src’s relative importance in particular
stages of CaP: oncogenesis, growth, survival, AI growth,
angiogenesis, and metastasis. Nevertheless, with cancer
treatments moving toward targeting specific pathways, it
is important that we continue investigating signaling path-
ways so that we can develop novel therapies through con-
tinued research.
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